Pendulum bet a probiotic could clear clinical trials like a drug; raised $54M Series C

A biotech that sequences the gut microbiome to design bacterial-strain supplements, sold direct to consumers as a subscription with coaching and lab testing included.

That a DNA-sequenced, clinically-validated microbiome supplement could bridge the gap between unregulated probiotics and prescription drugs.

$111M raised to date as of the April 2021 Series C, per CEO Colleen Cutcliffe, more than double the company's prior venture raises

Founded in San Francisco in 2013 by scientists Colleen Cutcliffe, James Bullard and John Eid, who applied DNA sequencing and computational biology to map how gut bacteria functions relate to metabolic health.

In 2020 Pendulum launched its first product, Pendulum Glucose Control, a medical probiotic clinically shown to lower blood sugar spikes and reduce A1C even alongside common diabetes medicines, with trial results published in BMJ Open Diabetes. Demand surged into 2021, the product kept selling out, and the company raised a $54M Series C led by Meritech Capital with existing backers Sequoia, True Ventures and Khosla Ventures, nearly doubling its total funding to $111M.

Cutcliffe's own daughter developed food allergies after infant antibiotics disrupted her microbiome, which is what pointed the founders at metabolic-health applications of microbiome science.

A published, peer-reviewed clinical trial let Meritech treat Pendulum like a next-generation pharmaceutical company rather than a supplement brand, per general partner Craig Sherman.

Real demand signal — the product selling out and 74% retention — validated the model before the company raised its largest round.

Sequencing-based precision let Pendulum target one condition (blood sugar) with evidence, instead of selling a generic probiotic blend on unverifiable claims.

In a category built on unverifiable claims, publishing a real clinical trial is a wedge, not just a compliance cost — it's what lets investors treat a supplement company like a pharma company.

As of 2021-04-07, Pendulum had raised $111M total, Glucose Control was in market with a published clinical trial behind it and consistently selling out, and the company was funding further manufacturing, marketing and a broader product pipeline aimed at other diseases.